<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014127</url>
  </required_header>
  <id_info>
    <org_study_id>RRK6607</org_study_id>
    <nct_id>NCT04014127</nct_id>
  </id_info>
  <brief_title>Coronary Microvascular Dysfunction in Chronic Kidney Disease</brief_title>
  <acronym>CRIB-FLOW</acronym>
  <official_title>Coronary Microvascular Dysfunction in Chronic Kidney Disease: The Chronic Renal Impairment in Birmingham Coronary Flow Reserve (CRIB FLOW) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Birmingham NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study assessing coronary microvascular function in healthy controls
      with normal kidney function, living kidney donors, pre-dialysis patients with chronic kidney
      disease stage 5 and patients on peritoneal dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical syndrome of uraemic cardiomyopathy is prevalent in end stage renal disease and
      is associated with pathological cardiovascular changes including left ventricular
      hypertrophy, diastolic dysfunction and diffuse interstitial fibrosis. These combine to confer
      an elevated cardiovascular risk, including an increased risk of sudden cardiac death.

      The cause of this increased cardiovascular risk is not clear but it is thought that coronary
      microvascular dysfunction may play a role. Coronary microvascular dysfunction is prevalent in
      many myocardial disease states, such as hypertrophic cardiomyopathy and heart failure with
      preserved ejection fraction, that share pathological similarities with uraemic
      cardiomyopathy.

      Coronary flow reserve, a marker of coronary microvascular function, can be assessed
      non-invasively using echocardiography techniques. Previous studies have shown a reduction in
      coronary flow reserve in patients with chronic kidney disease. However, it is not clear if
      kidney donors - individuals who have a reduced kidney function but do not have progressive
      kidney disease - also demonstrate microvascular dysfunction. Similarly, although there is
      some evidence that patients on dialysis have improved coronary flow reserve compared to
      patients with pre-dialysis chronic kidney disease stage 5, there has been limited
      investigation into the role of peritoneal dialysis on coronary flow reserve.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary flow reserve</measure>
    <time_frame>One baseline visit</time_frame>
    <description>Ultrasound-assessed coronary flow reserve. Data will be presented as a ratio (no unit) between maximal mean hyperemia flow velocity and baseline velocity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial blood flow</measure>
    <time_frame>One baseline visit</time_frame>
    <description>Ultrasound measurement of myocardial blood flow using myocardial contrast echocardiography. Data will be presented as dB/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>One baseline visit</time_frame>
    <description>Echocardiogram assessed left ventricular ejection fraction by Simpson's biplane method. Data will be presented as %.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulse wave analysis</measure>
    <time_frame>One baseline visit</time_frame>
    <description>Augmentation index measured using the Sphygmocor device. Data will be presented as %.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>One baseline visit</time_frame>
    <description>Pulse wave velocity measured using the Sphygmocor device. Data will be presented as m/s</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Disease, Chronic</condition>
  <condition>Myocardial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>25 controls with preserved renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney Donors</arm_group_label>
    <description>25 living kidney donors who have donated a kidney at least 12 months prior to enrollment in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-dialysis</arm_group_label>
    <description>25 patients with pre-dialysis chronic kidney disease stage 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <description>25 patients with chronic kidney disease stage 5 undergoing peritoneal dialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary flow reserve assessment</intervention_name>
    <description>Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Kidney Donors</arm_group_label>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Pre-dialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sphygmocor</intervention_name>
    <description>Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Kidney Donors</arm_group_label>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Pre-dialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electrocardiogram</intervention_name>
    <description>An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Kidney Donors</arm_group_label>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Pre-dialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Kidney Donors</arm_group_label>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Pre-dialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urinary albumin/creatinine ratio</intervention_name>
    <description>Urine will be analysed for albumin/creatinine ratio</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Kidney Donors</arm_group_label>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Pre-dialysis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma will be stored for future biomarker analysis including N terminal pro brain
      natriuretic peptide and troponin.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending University Hospitals Birmingham.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy control with normal renal function

          -  Living kidney donor who has donated &gt;12 months prior to enrolment in study

          -  Chronic kidney disease stage 5 who are pre-dialysis or on peritoneal dialysis

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Known ischaemic heart disease

          -  Diabetes mellitus

          -  Uncontrolled hypertension

          -  Evidence of 2nd or 3rd degree AV block or sick sinus syndrome in absence of a
             pacemaker

          -  History of allergic/adverse reaction to adenosine or Sonovue

          -  History of long QT syndrome

          -  Severe hypotension

          -  Significant valvular heart disease

          -  Significant chronic obstructive pulmonary disease or asthma with bronchospasm

          -  Unstable angina not controlled with medication

          -  Concurrent use of dipyridamole

          -  Decompensated heart failure

          -  Poor echo acoustic windows

          -  Chronic kidney disease stage 5 on haemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan N Townend, MD FRCP FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashwin Radhakrishnan, BM MRCP</last_name>
    <phone>+447756931470</phone>
    <email>a.radhakrishnan@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashwin Radhakrishnan, BM MRCP</last_name>
      <phone>+447756931470</phone>
      <email>a.radhakrishnan@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan N Townend, MD FRCP FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Birmingham NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Anna Price</investigator_full_name>
    <investigator_title>Co-Investigator</investigator_title>
  </responsible_party>
  <keyword>coronary flow reserve</keyword>
  <keyword>living kidney donation</keyword>
  <keyword>peritoneal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

